Igea Med
On 18 December 2020, Igea Med S.p.A. obtained admission to negotiate ordinary shares on AIM Italia, a multilateral negotiations system organized and managed by Borsa Italiana. Negotiations began on 22 December 2020.
Integrae SIM acted as Nomad and Global Coordinator.
The equivalent of the placement of a total of 259,000 shares and at the start date of the negotiations on AIM Italia PRO, the share capital of Igeamed S.p.A. will be represented by a total of 2,259,000 ordinary shares with a float of 11.47% for a planned capitalization equal to € 3,388,500.
The enterprise. Igeamed, a company of the Igeam Group, operates in the market of medicine for companies and provides companies with integrated consulting and engineering services for risk management and human resources. Igeamed, which operates entirely in Italy through a capillary structure with four operational headquarters throughout the country and, in particular, in Bari, Rome, Ravenna, and Milan, aims to promote corporate healthcare, representing the ideal partner to address the new needs of companies increasingly oriented towards social responsibility and the overall well-being of employees and the company system as a whole.
Ultima Ricerca Igea Med
BREAKING NEWS| In a press release dated February 26th, 2026, Pozzi Milano SpA, a company operating in the tableware sector and owner of the “EasyLife” and “Mascagni Casa” brands and, through its subsidiary Pozzi Brand Diffusion Srl, of the historic ‘Pozzi’ and “Castello Pozzi” brands, announced the approval of preliminary consolidated revenues as of December 31st, 2025, and certain unaudited management KPIs. Consolidated revenues for FY25 amounted to € 26.00 million, highlighting a progressive strengthening of the Group’s size and an excellent ability to generate volumes in the second half of the year, in line with the physiological seasonality that characterizes the sector. In line with the strategic guidelines communicated during the year, the Group also worked on strengthening its offering through investments in product development and expansion of distribution opportunities. Regarding to the Parent Company alone, Pozzi Milano recorded revenues of € 21.50 million, up 8.6% compared to € 19.84 million in the previous year, a significant result in light of a macroeconomic context still characterized by elements of uncertainty and final demand that is not fully expansive. The contribution of foreign markets remains central to the company’s strategy: after accounting for approximately 72.0% of sales revenues in 2024, exports stood at 66.0% in 2025, confirming their predominant role and consistency with the Group’s international positioning. More specifically, geographical expansion has been particularly evident in Western Europe, the Americas, and Central and Eastern Europe, areas in which the Company is gradually consolidating its commercial position. Confirming the international expansion strategy, in February 2026 the Company announced the acquisition of new orders from the Mexican market for a total value of approximately € 1.40 million. The transaction is part of an already established commercial relationship, continuing on from the orders finalized in January 2024 and January 2025, and further strengthens the Group’s presence in the Americas, which as of June 30th, 2025, accounted for almost 18.0% of revenues, with sales of approximately € 2.00 million and growth of 31.2% on an annual basis. The new order therefore confirms the solidity of the commercial positioning in the North American market and the consistency of execution with respect to the international development strategy. NFP stood at €0.50 million, a significant improvement compared to € 2.28 million recorded at June 30th, 2025. The significant reduction reflects strong operating cash flow generation in the second half of the year and particularly efficient working capital management. 2025 represents the first full year of the new Group structure, which includes Pozzi Brand Diffusion Srl, Mascagni Casa Srl, and Venditio SAS, outlining a broader and more integrated structure. Overall, the preliminary data confirm the solidity of the growth path and the management’s ability to effectively integrate recent acquisitions. Pending the assessment of the 2025 financial statements, we confirm our positive view on the stock: target price €1.25, BUY rating, Medium risk. |
